In January, we announced our new strategic partnership with Bruker to broaden access to our leading proteomics services & tools for biopharma and #biomarker customers.

In this exciting SpotLight episode, Biognosys’ CEO Oliver Rinner and Rohan Thakur, President of the Bruker Life-Science Mass Spectrometry division, discuss the many synergies of the new alliance and give an outlook of what the future might hold.

The case study elaborates on the latest study on lung cancer we performed with our high-throughput TrueDiscovery™ platform for immunopeptidome profiling from needle-sized biopsies. We identified > 11,000 Class I and > 9,000 Class II immunopeptides on average.

The brochure provides you with an overview of Biognosys’ history, including major milestones, our technology, as well as key facts about our offerings.

Download media kit

This comprehensive brochure provides an overview of our services, software, and kits offering.

Download Brochure

Our partnership with precision oncology expert Indivumed uniquely supports our mission of deciphering biological complexity and pushing the boundaries of what is possible with our proteomics solutions to accelerate drug discovery and development in oncology.

In this video, our CBO, Kristina, and Indivumed’s Senior Director Oncology Analytics, Daniel, highlight what they value and enjoy in our partnership.

Biognosys’ Head of Business Development & Sales, Ben Gonzales, recently sat down with NeoGenomics Laboratories’ Director of Scientific Affairs, Anna Juncker-Jensen, to discuss all things Biomarker Discovery. What are the biggest challenges researchers face today? And how can the collaboration between NeoGenomics and Biognosys help overcome them?

Watch the interview to hear their perspectives. To get to know more about this strategic partnership, click here.

Another episode of our SpotLight video series is out!

Let our Head of R&D LC-MS and Workflows, Roland Bruderer, guide you through discovering the fascinating world of tissue proteomics and explain how deep we can now explore the tissue proteomes to uncover enlightening insights.

Yes, today we are talking about immunopeptidomics! Our Principal Scientist, Marco Tognetti, is featured in our latest SpotLight series video to explain everything about this innovative application of our TrueDiscovery™ platform.

Are you looking for targets for personalized cancer immunotherapies or developing novel mRNA and peptide-based vaccines and cell-based therapies? We can help. Our Immunopeptidome Profiling solution offers the deepest identification of Class I and II peptides to step up your research journey!

Contact our experts at services@biognosys.com to learn how we can support you.

The case study elaborates on the results of our pan-cancer proteomics study. We analyzed 180 plasma samples from lung, breast, colorectal, pancreatic, and prostate cancer using our next-generation TrueDiscovery™ platform to discover actionable biomarkers.

E-Poster #TP 025 presented at ASMS 2021

Presenter: Roland Bruderer
Session: Biomarkers: Discovery
Date: Tuesday, November 2

The brochure provides you with an overview of the key features and benefits of our next-generation Biomarker Discovery solutions. In addition, the brochure elaborates on our deep and reproducible proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.

Biomarker Discovery Brochure

New: Spectronaut^® 19

Unlock Your Data's True Story

New: Spectronaut^® 19

Unlock Your Data's True Story

Learn More